NDATOPICALCREAM
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
6/8 — Strong
AKLIEF (trifarotene) by Galderma is (rar), with particular activity at the gamma subtype of rar. First approved in 2019.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKLIEF (trifarotene) is a topical retinoid cream that targets retinoic acid receptor-gamma (RAR-γ) to modulate cell differentiation and inflammation in acne. It is indicated for acne treatment via topical application. The exact mechanism by which trifarotene ameliorates acne remains incompletely understood, though RAR stimulation is central to its therapeutic effect.
$0.198MPart D
Peak6.9 years to LOEProduct is at peak lifecycle stage with minimal Part D utilization, suggesting limited market penetration and potential for growth-phase team expansion.
Mechanism of Action
(RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results in modulation of target genes which are associated with various processes, including cell differentiation and mediation of inflammation. The exact process by which trifarotene ameliorates acne is unknown.
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris
Started Sep 2025
561 enrolled
Acne Vulgaris
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
Started Sep 2022
807 enrolled
Acne Vulgaris
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
Started Dec 2021
123 enrolled
Acne Vulgaris
Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
Started May 2021
121 enrolled
Acne Vulgaris
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
Started Jul 2020
202 enrolled
Acne Vulgaris
Worked on AKLIEF at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.